Epidemiological studies strongly suggest that chronic stress has significant negative influences on the onset, progression and mortality of human tumors. However, the role and underlying mechanisms of chronic stress in tumorigenesis remain elusive. Employing chronic restraint in mice, a well-established mouse model to induce chronic stress, we found that chronic stress promotes IR-induced lymphoma formation in mice. Tumor suppressor p53 and its signaling pathway play a critical role in tumor suppression. Our recent studies found that chronic restraint greatly decreases wild type p53 (wtp53) protein levels and function, which is an important mechanism by which chronic stress promotes tumorigenesis in tumors containing wtp53. p53 is the most frequently-mutated gene in human tumors; over 50% of all tumors harbor p53 mutations. Many tumor-associated mutant p53 (mutp53) proteins not only lose the tumor suppressive function of wtp53, but also gain new activities to promote tumorigenesis, defined as gain-of-function (GOF). Mutp53 proteins often accumulate to high levels in tumors which is critical for mutp53 GOF. Interestingly, our preliminary data show that chronic stress promotes mutp53 protein accumulation and GOF in tumorigenesis. Chronic stress results in the prolonged elevation of catecholamines, which activates -adrenergic receptor ( -AR) and its signaling to mediate many effects of chronic stress. Our preliminary studies suggest that catecholamines mediate the promoting effect of chronic stress on mutp53 protein accumulation and GOF. Based on our preliminary studies, we hypothesize that chronic stress promotes tumorigenesis, and the up-regulation of mutp53 protein levels and GOF in tumorigenesis by catecholamines is an important underlying mechanism for tumors containing mutp53. In this proposed study, we will 1) test the hypothesis that chronic stress preferentially promotes tumorigenesis in tumors containing mutp53 through promoting mutp53 accumulation and GOF by employing mouse tumor models; 2) test the hypothesis that the up-regulation of mutp53 protein levels and GOF by catecholamines is an important mechanism by which chronic stress promotes tumorigenesis in tumors containing mutp53; 3) determine the mechanisms by which catecholamines promote mutp53 accumulation and GOF. We expect that this study will provide direct evidence that chronic stress promotes tumorigenesis of mutp53 containing tumors, and validate that the up-regulation of mutp53 protein levels and GOF by catecholamines is an important mechanism. Blocking chronic stress and/or -AR signaling could be a novel therapeutic strategy for mutp53 containing tumors. This study has the potential to provide pivotal molecular targets for disrupting stress/neurohormone signaling in the tumor microenvironment to treat undruggable mutp53 containing tumors.
This proposal aims to understand the role of chronic stress in the development and progression of tumors, especially those containing mutant p53, and elucidate its underlying mechanisms. We expect that this study will provide direct evidence that chronic stress promotes tumorigenesis of tumors containing mutp53, and validate the up-regulation of mutp53 protein levels and function in promoting tumorigenesis as an important mechanism. This study has the potential to provide pivotal molecular targets for disrupting stress/neurohormone signaling in the tumor microenvironment to treat undruggable mutp53 containing tumors.
| Liu, Juan; Zhang, Cen; Hu, Wenwei et al. (2018) Parkinson's disease-associated protein Parkin: an unusual player in cancer. Cancer Commun (Lond) 38:40 |
| Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7: |
| Liu, Juan; Zhang, Cen; Zhao, Yuhan et al. (2017) Parkin targets HIF-1? for ubiquitination and degradation to inhibit breast tumor progression. Nat Commun 8:1823 |
| Yue, Xuetian; Zhang, Cen; Zhao, Yuhan et al. (2017) Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. Genes Dev 31:1641-1654 |
| Yue, Xuetian; Zhao, Yuhan; Xu, Yang et al. (2017) Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. J Mol Biol 429:1595-1606 |
| Zhao, Y; Zhang, C; Yue, X et al. (2015) Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53. Cell Death Differ 22:1824-36 |
